Microbot Medical (NASDAQ:MBOT) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

Microbot Medical (NASDAQ:MBOT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

Other research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. B. Riley Financial reissued a “buy” rating and set a $4.00 price target (down from $5.00) on shares of Microbot Medical in a report on Friday, August 14th. Zacks Research cut Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Loop Capital set a $4.00 price target on Microbot Medical in a research report on Wednesday, June 3rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Microbot Medical in a research note on Wednesday, August 19th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Microbot Medical presently has a consensus rating of “Hold” and an average target price of $6.38.

Check Out Our Latest Report on Microbot Medical

Microbot Medical Stock Performance

Shares of MBOT opened at $1.44 on Friday. The firm has a market cap of $96.72 million, a PE ratio of -6.00 and a beta of 1.03. The company’s 50 day simple moving average is $1.71 and its 200-day simple moving average is $2.02. Microbot Medical has a 12-month low of $1.44 and a 12-month high of $4.67.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. As a group, equities research analysts forecast that Microbot Medical will post -0.29 EPS for the current fiscal year.

Institutional Trading of Microbot Medical

Several hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. purchased a new stake in shares of Microbot Medical in the first quarter valued at approximately $28,000. American Century Companies Inc. purchased a new position in Microbot Medical in the second quarter worth $32,000. Zacks Investment Management purchased a new position in Microbot Medical in the third quarter worth $33,000. Man Group plc acquired a new stake in Microbot Medical in the fourth quarter valued at $35,000. Finally, Squarepoint Ops LLC acquired a new stake in Microbot Medical in the third quarter valued at $37,000. 16.30% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

Featured Stories